重大事件
外國發行人報告
6-K
2026-07-06
諾和諾德提交6-K，更新150億丹麥克朗股份回購計劃進度
AI 繁中摘要
Novo Nordisk 提交 6-K 表格，更新股份回購計劃進度 📊
丹麥製藥巨頭 Novo Nordisk 於 2026 年 7 月 6 日向 SEC 提交 6-K 文件，報告其最新股份回購計劃的執行情況。該計劃自 2026 年 5 月 6 日啟動，屬於 2026 年 2 月 4 日開始的為期 12 個月、總額上限 150 億丹麥克朗（DKK）回購計劃的一部分。本次計劃（至 2027 年 2 月 1 日）授權回購最多約 112 億丹麥克朗的 B 股。
📌 最新交易詳情（2026 年 6 月 29 日至 7 月 3 日）：
- 每日回購 20 萬股，平均價格介乎 314.24 至 326.71 丹麥克朗。
- 該週累計交易價值約 3.21 億丹麥克朗。
- 自本輪計劃啟動以來，累計回購 825 萬股，總交易價值約 24.2 億丹麥克朗。
📈 整體進度（截至 2026 年 7 月 3 日）：
- 自 2026 年 2 月 4 日起，已回購合共 23,009,179 股 B 股。
- 平均購買價為每股 270.32 丹麥克朗，累計交易價值約 62.2 億丹麥克朗。
- 公司目前持有 40,194,480 股庫存 B 股（每股面值 0.10 丹麥克朗），約佔總股本 44.65 億股的 0.9%。
此回購計劃反映 Novo Nordisk 對自身價值的信心，並透過減少市場流通股份，有望提升每股盈利及股東回報。投資者應留意回購進度及未來公告。
展開英文正文
6-K 1 f6k_070626.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 6, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 6 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 29 June 2026, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 7,250,000 2,098,848,921 29 June 2026 200,000 314.24 62,847,300 30 June 2026 200,000 318.15 63,630,624 1 July 2026 200,000 320.42 64,083,705 2 July 2026 200,000 325.11 65,022,718 3 July 2026 200,000 326.71 65,342,713 Accumulated under the programme 8,250,000 2,419,775,981 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 40,194,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares. Page 2 of 2 Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 3 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 23,009,179 B shares at an average share price of DKK 270.32 per B share equal to a transaction value of DKK 6,219,775,971. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown Liz Skrbkova (US) +45 3079 9289 +1 609 917 0632 [email protected] [email protected] Investors: Michael Novod Jacob Martin Wiborg Rode +45 3075 6050 +45 3075 5956 [email protected] [email protected] Ida Schaap Melvold Sina Meyer +45 3077 5649 +45 3079 6656 [email protected] [email protected] Alex Bruce Christoffer Sho Togo Tullin +45 3444 2613 +45 3079 1471 [email protected] [email protected] Frederik Taylor Pitter Mads Berner Bruun +1 609 613 0568 +45 3075 2936 [email protected] [email protected] Novo Nordisk A/S Investor Relations Novo Allé 1 2880 Bagsværd Denmark Telephone: +45 4444 8888 www.novonordisk.com CVR no: 24 25 67 90 Company announcement No 41/ 2026 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: July 6, 2026 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer